[1] |
Goodarzi MO,Dumesic DA,Chazenbalk G,et al.Polycystic ovary syndrome:etiology, pathogenesis and diagnosis[J].Nat Rev Endocrinol,2011,7 (4):219–231.
|
[2] |
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment[J]. Fertil Steril,2005,83(5):1454–1560.
|
[3] |
Pasquali R,Stener-Victorin E, Yildiz BO,et al.PCOS forum: research in polycystic ovary syndrome today and tomorrow[J].Clin Endocrinol (Oxf),2011,74(4): 424–433.
|
[4] |
Legro RS, Arslanian SA, Ehrmann DA,et al.Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2013,98(12):4565–4592.
|
[5] |
Hughes C, Elgasim M, Layfield R,et al.Genomic and post-genomic approaches to polycystic ovary syndrome-progress so far: mini review[J]. Hum Reprod,2006,21(11): 2766–2775.
|
[6] |
Swinbanks D.Government backs proteome proposal[J]. Nature,1995, 378(6558):653.
|
[7] |
Weiss W, Görg A. High-resolution two-dimensional electrophoresis[J].Methods Mol Biol, 2009,564:13–32.
|
[8] |
Görg A,Weiss W,Dunn MJ.Current two-dimensional electrophoresis technology for proteomics[J]. Proteomics,2004, 4(12): 3665–3685.
|
[9] |
Gloerich J,Wexers RA, Smeitink JA,et al. Proteomic of approaches to study genetic and metabolic disorders[J]. J Proteome Res,2007,6(2):506–512.
|
[10] |
Suss C,Solimena M.Proteomic profiling of beta-cells using a classical approach- two-dimensional gel electrophoresis[J].Exp Clin Endocrinol Diabetes,2008,116:13–20.
|
[11] |
Wong SC, Chan CM, Ma BB,et al. Advanced proteomic technologies for cancer biomarker discovery[J]. Expert Rev Proteomics, 2009,6(2):123–134.
|
[12] |
Wang H, Hanash S. Multi dimensional liquid phase based separations in proteomics[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2003,787(1):11–18.
|
[13] |
Choi DH,Lee WS, Won M,et al. The apolipoprotein A-Ⅰ level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis[J]. J Proteome Res,2010, 9(9):4329–4336.
|
[14] |
Chapman K.The ProteinChip Biomarker System from Ciphergen Biosystems:a novel proteomics platform for rapid biomarker discovery and validation[J]. Biochem Soc Trans,2002, 30(2):82–87.
|
[15] |
Ma X, Fan L, Meng Y,et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome[J]. Mol Hum Reprod,2007, 13(8): 527–535.
|
[16] |
Kim YS, Gu BH, Choi BC,et al. Apolipoprotein A-Ⅳ as a novel gene associated with polycystic ovary syndrome[J].Int J Mol Med,2013,31(3):707–716.
|
[17] |
Dai G, Lu G. Different protein expression patterns associated with polycystic ovary syndrome in human follicular fluid during controlled ovarian hyperstimulation[J]. Reprod Fertil Dev,2012,24(7): 893–904.
|
[18] |
Corton M, Botella-Carretero JI, Lopez JA,et al. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry[J]. Hum Reprod,2008,23(3): 651–661.
|
[19] |
Insenser M, Martinez-Garcia MA, Montes R,et al. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation[J]. J Clin Endocrinol Metab,2010,95(8): 3863–3870.
|
[20] |
Montes-Nieto R, Insenser M,Martínez-García MÁ,et al.A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes[J]. J Clin Endocrinol Metab,2013,98(3): E576–E585.
|
[21] |
Zhao S, Qiao J, Li M, et al.Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry[J]. Fertil Steril,2007,88(1): 145–151.
|
[22] |
Liu JJ,Ma X,Cai LB, et al. Downregulation of both gene expression and activity of HSP 27 improved maturation of mouse oocyte in vitro[J]. Reprod Biol Endocrinol,2010, 8:47.
|
[23] |
Insenser M, Martínez-García MA,Montes R,et al. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation[J]. J Clin Endocrinol Metab, 2010, 95(8):3863–3870.
|
[24] |
Atiomo WU,Khalid S,Ziauddin A,et al.Framework for a systems approach to proteomic biomarker profiling in polycystic ovary syndrome[J].Expert Rev Proteomics,2009,6(5):469–499.
|
[25] |
秦芬,丘彦,杨曦,等.多囊卵巢综合征差异蛋白质组分析[J].重庆医科大学学报,2010,35(1):22–24.
|
[26] |
张丽静,丘彦.多囊卵巢综合征胰岛素抵抗差异蛋白的分析[J].重庆医科大学学报,2011,36(2):145–147.
|
[27] |
Matharoo-Ball B, Hughes C,Lancashire L,et al.Characterization of biomarkers in polycystic ovary syndrome(PCOS) using multiple distinct proteomic platforms[J].J Proteome Res,2007,6(8): 3321–3328.
|
[28] |
Galazis N, Afxentiou T, Xenophontos M,et al.Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome[J]. Eur J Endocrinol,2013,168(2): R33–R43.
|
[29] |
Galazis N, Olaleye O, Haoula Z,et al. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration[J]. Fertil Steril,98(6):1590–1601.
|
[30] |
Galazis N, Pang YL, Galazi M,et al. Proteomic biomarkers of endometrial cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration[J]. Gynecol Endocrinol, 2013, 29(7): 638–644.
|
[31] |
Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects[J]. Mol Cell Proteomics,2002,1(11): 845–867.
|